Dasatinib for elderly CML: can reducing dose increase viable patients?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Dasatinib (Sprycel) was well tolerated and delivered molecular response to most patients aged ≥65 y with chronic myeloid leukemia (CML) at the low dose of ≤20 mg/d.

Why this matters

  • Dasatinib is significantly more potent than imatinib in terms of in vitro BCR-ABL inhibitio...